Continuous retinoic acid induces the differentiation of mature regulatory monocytes but fails to induce regulatory dendritic cells by Zachary C VanGundy et al.
VanGundy et al. BMC Immunology 2014, 15:8
http://www.biomedcentral.com/1471-2172/15/8RESEARCH ARTICLE Open AccessContinuous retinoic acid induces the
differentiation of mature regulatory monocytes
but fails to induce regulatory dendritic cells
Zachary C VanGundy1, Mireia Guerau-de-Arellano2, Julie D Baker1, Heather R Strange1, Susan Olivo-Marston3,
Dillon C Muth1 and Tracey L Papenfuss1*Abstract
Background: Myeloid cells (MC) have potent immunoregulatory abilities that can be therapeutically useful to treat
inflammatory disease. However, the factors which promote regulatory myeloid cell differentiation remain poorly
understood. We have previously shown that estriol (E3) induces mature regulatory dendritic cells in vivo. To
determine whether additional steroid hormones could induce mature regulatory myeloid cells, we investigated the
effects of retinoic acid (RA) on MCs. Retinoic acid is a steroid hormone important in regulating mucosal immunity
in the gut and promoting myeloid differentiation. We hypothesized that the presence of RA during differentiation
would promote the formation of mature regulatory myeloid cells (MCregs).
Methods: To determine RA’s ability to induce regulatory myeloid cells, we differentiated bone marrow progenitor
cells with granulocytic-macrophage colony-stimulating factor (GM-CSF) under the influence of RA. We found that
day 7 MCs differentiated in the presence of RA had an increase in the percent positive and relative expression levels
of both maturation (CD80, CD86, and MHCII) and inhibitory (PD-L1 and PD-L2) markers compared to control cells.
Functionally, these day 7 RA MCs expressed increased intracellular IL-10, induced regulatory T cells in vitro compared
to controls and suppressed the proliferation of responder immune cells even after inflammatory challenge with LPS.
Conclusion: RA induced mature regulatory myeloid cells that were suppressive and had a CD11b+ CD11c-
Ly6C low/intermediate monocyte phenotype. Surprisingly, RA CD11c+ dendritic cells were not suppressive and could
contribute to enhanced proliferation. These results suggest that continuous RA has unique effects on different myeloid
populations during monopoeisis and dendropoiesis and promotes a population of regulatory monocytes.
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Myeloid cells (MCs) are a diverse population of cells that
form during hematopoiesis and play a critical role in
host defense. Comprised of granulocytes, mononuclear
phagocytes and their precursors, MCs are innate im-
mune cells that have an important role in promoting in-
flammation and the induction of adaptive immune
responses. Inflammatory MCs are induced and increased
in numbers following exposure to exogenous (e.g. patho-
gens) or endogenous “danger” (e.g. post-necrotic release* Correspondence: papenfuss.1@osu.edu
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These and other environmental factors present within
peripheral tissue and bone marrow impact granulopoi-
esis, monopoiesis and dendropoiesis to influence the ul-
timate fate of inflammatory granulocytes, monocytes/
macrophages and DCs, respectively. While inflammatory
MCs have been well characterized, within the last several
years the potent regulatory abilities of these cells has in-
creasingly been recognized. Such regulatory MCs (MCregs)
are a diverse population of cells with the ability to control
inflammation and, thus, are a promising target to treat
a wide array of inflammatory diseases. To date, how-
ever, factors involved in the differentiation of MCreg
populations remain poorly understood.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited.
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ology and in function. Regulatory, tolerogenic, type II or
steady-state are terms applied to regulatory populations
of DCs, macrophages, monocytes, and their precursors
[1-3]. By and large, the regulatory abilities of macro-
phages, and more recently, DCs have been most thor-
oughly studied. First described over 30 years ago,
alternatively activated macrophages are able to promote
wound healing and resolve inflammation [4,5]. Over the
last 10 years the regulatory abilities of DCs and their
therapeutic potential have been the focus of many stud-
ies [2,6]. Monocytes are circulating myeloid cells that
give rise to tissue macrophages and DCs. Monocytes
have been recognized as a contributor to the inflammatory
responses, and are now known to contribute to immune
regulation [7]. MCregs can regulate immune responses
through the production of soluble regulatory factors (e.g.
IL-10, TGF-beta, indoleamine 2,3 deoxygenase (IDO), ar-
ginase, nitric oxide (NO), etc.), expression of inhibitory or
regulatory cell surface molecules (e.g. PD-L1, PD-L2) and
induction other regulatory cells (e.g. regulatory T cells;
Tregs) or enhance regulatory feed-back loops [8,9]. At
present, MCregs are identified based on combination of
phenotype and function, with no equivalent to Treg FoxP3
marker being as yet identified [10-13]. Through cell-cell
interactions and the production of soluble immunoregula-
tory molecules, MCregs have very potent and diverse
means of inducing immune regulation. However, much re-
mains to be characterized about factors controlling MCreg
induction and how different MCreg subsets regulate im-
mune responses. Given that MCreg therapy has the poten-
tial to diminish disease in the 100+ millions of individuals
impacted by immune-mediated, chronic inflammatory
and autoimmune diseases worldwide, it is critical to deter-
mine the factors which govern the induction and function
of these cells [14-16]. The therapeutic potential of MCregs,
has been described in several experimental models of in-
flammatory and autoimmune disease. Specifically, MCregs,
including MDSC, conventional DCs, lung-resident tissue
macrophages, monocytes, and plasmacytoid DCs have all
been shown to impact disease course in animal models of
diabetes [17], colitis [18], allergic asthma [19], experimen-
tal autoimmune disease [20], and rheumatoid arthritis
[21] respectively.
For many MCregs, an arrest in immature and/or altered
functionality contributes to their regulatory abilities [22,23].
Glucocorticoids, vitamin D and IL-10 are the most com-
mon means to induce these immature MCregs. These al-
tered MCregs cells have decreased expression levels of
maturation/activation markers CD80, CD86 and MHC
class II [2,24-28]. Additionally, these immature MCregs
can have reduced inflammatory cytokine expression
[29,30], overall blunted function, induce Tregs and sup-
press the action of other immune cells. However, aprimary concern with using immature MCregs for ther-
apy is that they may mature into inflammatory MCs
under inflammatory disease conditions. Such inflamma-
tory MCs could then actually exacerbate the very in-
flammatory disease they were used to treat [2,22,23,31].
Thus, mature (and stable) MCregs may avoid such con-
cerns but, to date only a handful of studies have signifi-
cantly explored the induction of such mature MCregs
[18,22,32]. Typically, mature MCregs have been induced
by combining traditional immature MCreg induction
protocols with the addition of inflammatory stimuli
such as LPS or TNF-alpha [33,34]. Our laboratory has
focused on identifying non-inflammatory systems to in-
duce mature MCregs and we have previously found that
estriol (E3), a steroid hormone of pregnancy, produce
mature activated DCregs [35]. These E3 DCregs main-
tained their regulatory abilities within an inflammatory
environment and protected mice against the inflammatory
autoimmune disease, experimental autoimmune en-
cephalomyelitis (EAE) [35]. Although E3 shows prom-
ise, the fact that there are limitations on using estrogens
broadly in the human patient population necessitated
investigating alternative means of inducing mature stable
MCreg populations.
All-trans retinoic acid (RA) is a steroid hormone metab-
olite of vitamin A that plays both an important role during
embryonic development and has recently been identified
as the key metabolite regulating immune responses at mu-
cosal sites [36-38]. RA is a logical candidate for inducing
mature MCregs given its defined role in both mucosal im-
munoregulation and its ability to promote myeloid cell
differentiation and maturation. Within the gut, RA influ-
ences the balance between Tregs and Th17 cells, B cell iso-
type switching, antibody production and mucosal homing
of numerous immune cells [6,37,39-43]. Mucosal myeloid
cells are largely responsible for producing local RA which
acts in a paracrine and autocrine manner to regulate mu-
cosal immune responses [6,37]. Although mucosal DCs
produce much of the RA required for immune regulation
at mucosal sites, much less is known about RA’s direct im-
pact on MC populations at both mucosal and non-
mucosal sites [9,19,39,40].
RA regulates myeloid cell survival and promotes the
differentiation of immature myeloid cells into mature popu-
lations of DCs, macrophages and granulocytes [18,44-46].
Additionally, RA appears to be required for the production
of mature phagocytes in the bone marrow through its ef-
fects on MHC class II and co-stimulatory molecule expres-
sion [47]. Therapeutically, RA has long been used to treat
myeloid leukemia given that it promotes myeloid cell differ-
entiation and maturation [48,49]. More recently, it has been
used to promote the differentiation of immature myeloid
cells (i.e. myeloid derived suppressor cells; MDSCs) in can-
cer patients to diminish immunosuppressive MDSC effects
VanGundy et al. BMC Immunology 2014, 15:8 Page 3 of 14
http://www.biomedcentral.com/1471-2172/15/8[36,44,50-53]. Given RA’s important roles in both mucosal
immunoregulation and myeloid cell differentiation we hy-
pothesized that RA would induce mature MCregs.
Using an in vitro model to induce differentiation of
MC populations (i.e. DCs, macrophages and monocytes),
we evaluated the ability of RA to generate mature
MCregs [42,54]. We demonstrated that bone marrow
cells differentiated with GM-CSF for 7 days in the pres-
ence of RA had an activated regulatory phenotype (i.e.
increased CD80, CD86, MHC class II, PD-L1 and PD-
L2), produced increased IL-10, increased the induction
of Treg and suppressed the proliferation of responder im-
mune cells. We found that the suppressive population
was a small but potent CD11b+ CD11c- Ly6Clow/intermediate
population whose phenotype is consistent with a regula-
tory monocyte. Surprisingly the CD11c+ DCs were not
suppressive. Taken together these results demonstrate a
differential effect of RA during monopoiesis and dendro-
poiesis which results in the induction of regulatory mono-
cytes but not regulatory DCs.
Results
Differentiation with retinoic acid induced mature
activated regulatory myeloid cells
Given that RA is a regulator of mucosal immunity and
influences myelopoiesis, we hypothesized that RA would
induce a population of mature MCregs. Day 6–7 BM cells
differentiated with GM-CSF in the presence of RA were
able to suppress the proliferation of responder immune
cells and this suppression was markedly greater than ei-
ther control or E3 treated cells (Figure 1A). The ability
of RA differentiated cells to suppress proliferation was
apparent regardless of whether responder immune cells
were stimulated with either peptide or anti-CD3. Inter-
estingly, cells treated with E3 suppressed proliferation
after stimulation with peptide but not anti-CD3 (Figure 1A).
We next determined whether the RA differentiated cells
remained regulatory when exposed to the inflammatory
stimulus LPS. Figure 1B shows that RA differentiated cells
maintained their ability to suppress proliferation even
after exposure to LPS challenge and that this was present
following stimulation of co-cultures with either pep-
tide or anti-CD3. This effect was entirely lost in E3
treated cells. These results suggest that RA differenti-
ated cells are more potent and stable than E3 differen-
tiated cells and that RA differentiated cells maintain
their regulatory ability following exposure to an in-
flammatory stimulus.
Given that increased IL-10 is seen in E3 DCregs [35]
and other MCreg populations [50,55] we next evaluated
whether RA induced an increase number of IL-10+ cells.
Figure 1C shows that RA differentiated cells had an in-
creased percentage of IL-10-producing cells compared
to either media or E3 control cells. We next evaluatedwhether RA differentiated cells could increase Treg
numbers. We found that RA differentiated cells were
able to induce a significant increased percentage of
FoxP3+ cells following a 5 day culture with naïve im-
mune cells (Figure 1D). Cells differentiated in vitro in
the presence of E3 failed to significantly increase either
IL-10+ cells or induce Treg cells (Figures 1C, D). These
results show that RA differentiated cells suppressed the
proliferative abilities of responder immune cells and in-
duced FoxP3+ (Treg) cells.
To determine whether these RA differentiated cells
were mature, we evaluated the cell surface expression of
maturation markers CD80, CD86 and MHC class II and
inhibitory markers PD-L1 and PD-L2. RA differentiated
cells demonstrated an increased percentage of CD80+,
CD86+ and MHC class II+ (Figure 2A), indicating that
an increased proportion of the cells were mature and/or
activated in comparison to E3 or control cells. Addition-
ally, there were increases in the mean fluorescence in-
tensity (MFI) of CD80, CD86 and MHC class II in RA
differentiated cells as depicted in Figures 2C and D, indi-
cating that the relative expression levels on a per cell
basis were increased in RA differentiated cells. Although
E3 differentiated cells had mildly increased expression
levels of CD80, CD86 and MHC class II, RA differenti-
ated cells had consistently higher levels than either E3
differentiated or control cells. To confirm that RA dif-
ferentiated cells demonstrated an “activated regulatory”
phenotype as previously described for E3, we evaluated
the expression of inhibitory co-stimulatory molecules
PD-L1 and PD-L2 [35]. RA increased the percentage of
PD-L1+ cells (but not PD-L2+) (Figure 2B) and the MFI
of both PD-L1 and PD-L2 (Figure 2C, D) compared to
E3 or media controls. These results demonstrate that
during differentiation RA induces a population of ma-
ture activated MCregs that suppress the proliferation of
responder immune cells even in the face of inflammatory
challenge. Additionally, our data shows that although both
RA and E3 may induce MCregs which suppress prolifera-
tion (Figure 1A) RA MCregs appear to have superior regu-
latory abilities compared to E3 MCregs.
CD11b+ but not CD11c+ cells were the suppressive
population
The in vitro differentiation of bone marrow cells with
GM-CSF is a commonly used protocol to produce large
numbers (>80%) of highly enriched CD11c+ DCs [38,56]
that, as a population, are considered immature DCs.
However, our data demonstrated that while approximately
80-90% of the cells were CD11c+, the remaining
10-20% were CD11c- but still CD11b+ (Additional file
1: Figure S1A). To determine whether the MCregs induced
by RA were DCs, we purified CD11c+ cells from day 7
differentiated cells and cultured them with responder
Figure 1 RA treatment of bone marrow myeloid cells produces a regulatory myeloid cell population. Bone marrow cells were
differentiated in the presence of GM-CSF with or without 100 nM of either estriol or retinoic acid over 6–7 days of differentiation to generate
MCs, E3 MCregs or RA MCregs. A portion of these cells were also challenged with LPS in the last 24 hours of differentiation. BM-MCs (A) and
LPS-stimulated BM-MCs (B) were co-cultured with responder immune cells containing T cell receptor transgenic CD4+ T cells specific for peptide
for 96 hours with media, antigen or anti-CD3 stimulation and then pulsed with H3 thymidine in the final 18 hours of culture. In MCs, E3 MCregs
and RA MCregs, (C) the relative percentage of IL-10
+ cells was determined and (D) the ability of these cells (after a 5 day co-culture) to induce
FoxP3+ cells from naïve FoxP3-EGFP reporter immune cells was determined by flow cytometry. Data are representative of at least three separate
experiments * = p < 0.05.
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“DCregs” have been described [9,36,57], we found that
RA-treated CD11c+ cells were not the suppressive cell
population (Figure 3A). In all experiments, RA-treated
CD11c+ cells failed to suppress proliferation and had
variable to no effect on proliferation with some experi-
ments actually demonstrating enhanced proliferation
(data not shown). Phenotypic evaluation of these
CD11c+ cells showed no difference in percentage
(Figure 3B) or expression levels of CD80, CD86, MHC
class II, PD-L1 and PD-L2 compared to media controls.
To determine the source of the suppressive MCregs, we
evaluated the CD11c- population and found that the
RA CD11c- cells suppressed proliferation of responder
cells (Figure 3C). These CD11c- cells had a marked
(>30%) increase in the percentage of CD80+, CD86+,
MHC class II+ and PD-L1+ cells (with no differences inPD-L2+ cells) (Figure 3D) when differentiated with RA,
consistent with an activated regulatory phenotype in these
cells described previously [35]. In contrast, levels of CD80,
MHC class II and PD-L1 did not change, remaining
consistently high (>80%) in RA versus control MCs.
(Figure 3B). These data suggest that RA present during
GM-CSF differentiation increased an activated regula-
tory phenotype in the CD11c- (non-DC) populations.
Both differentiated and precursor populations within
the bone marrow are predominantly but not completely
CD11b+ (>90%) (Additional file 1: Figure S1A). To de-
finitively isolate the effects of CD11b+ CD11c- cells, we
serially purified CD11b+ cells from the CD11c- fraction
and evaluated their phenotype and function. As expected,
the increases in the percentage of CD80+, CD86+, MHC
class II+ and PD-L1+ cells seen in Figure 3D was also
seen in the CD11b+ CD11c- serially purified population
Figure 2 RA treatment of bone marrow myeloid cells produces mature myeloid cells. Bone marrow cells were differentiated in the
presence of GM-CSF with or without 100 nM of either estriol or retinoic acid over 6–7 days of differentiation. Cells were routinely stained for flow
cytometry using antibodies against CD11c-, CD11b+, CD80, CD86, MHC class II, PD-L1 and PD-L2, run of a BD Accuri C6 flow cytometer and
phenotypic profiles evaluated using the Cflow plus software program. Cells were evaluated for the presence of maturation (activation) markers
(A) CD80, CD86 MHCII, and the inhibitory co-stimulatory markers (B) PD-L1and PD-L2. (C) Mean fluorescence intensity (MFI) was determined and
relative expression shown by overlays of cell treatment groups and MFI values (D). Data are representative of at least three separate experiments.
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these cells to influence CD4 and CD8 responses. We
found that the CD11b+ CD11c- population was able to
suppress the proliferation of responder immune cells
(Figure 4B) and could modify the cytokine profile of T
cells. The proliferating CD4+ responder immune cells
cultured with RA CD11b+ CD11c- cells were also shown
to have reduced expression of IL-17 IFN-gamma
(Figure 4C) and IL-10 (Additional file 2: Figure S2) but
no change in IL-4 production as determined by intracel-
lular cytokine staining (Figure 4C). Intracellular IL-10
and FoxP3+ cells were also increased as expected
(Additional file 2: Figure S2A and S2B, respectively).
We also evaluated the ability of RA CD11b+ CD11c-
cells to influence CD8+ T cell responses. Figure 4D
demonstrates reduced cytotoxicity in CD8+ T cells cul-
tured with RA CD11b+ CD11c- cells. Taken together, these
results suggest that RA induced an activated regulatory
population of CD11b+ CD11c- cells that were able to sup-
press both CD4+ and CD8+ adaptive immune responses.CD11b+ CD11c-Ly6Clow/intermediate were the primary
population responsible for suppression
Although used primarily to induce large numbers of
DCs, differentiation with GM-CSF can potentially pro-
mote the differentiation of a mixture of granulocytes,
monocytes, macrophages and DCs [42,54,56,58-60] In
our GM-CSF cultures, we found that Ly-6G+ granulo-
cytes were no longer present in CD11b+ cells at day 7 of
differentiation (Additional file 1: Figure S1B), indicating
that granulocytes were not responsible for the suppres-
sion seen [61,62]. To determine whether monocytes
were present and may be responsible for the suppressive
effects, we evaluated day 7 non-adherent cells sorted
based on their relative expression of the monocyte
marker Ly-6C. Ly-6C expression levels have been shown
to correlate with cellular function and maturation level
where Ly-6Chigh monocytes are inflammatory and Ly-
6Clow monocytes are steady-state or regulatory [7,63].
Figure 5A shows that the presence of RA during differ-
entiation increased the percentage of cells expressing
Figure 3 RA mediated suppression of T cell proliferation is not mediated by CD11c+ BM-MCs. BM-MCs were magnetically separated with
CD11c+ beads. Purity of CD11c+ and CD11c- cells was confirmed and cells analyzed on the BD Accuri C6 Flow cytometer, Purified CD11c+ (A)
and CD11c- (C) were co-cultured with responder immune cells for 96 hours with media or anti-CD3 stimulation and then pulsed with H3 thymidine in
the final 18 hours of culture; and the relative percentages of CD11cs+ (B) and CD11c- (D) cells expressing maturation markers CD80, CD86 MHCII,
PD-L1and PD-L2 were determined. Data are representative of three separate experiments* = p < 0.05.
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whether the increase in these cells was responsible for
the suppression seen in the CD11b+ CD11c- population,
we sorted cells based on Ly-6Clow, Ly-6Cintermediate, and
Ly-6Chigh expression patterns. Figure 5B demonstrates
that both Ly-6Clow and Ly-6Cintermediate cells were able
to suppress up to a 6-fold decrease in proliferation of
responder cells following antigenic stimulation while
Ly-6Chigh cells failed to influence peptide-specific prolif-
eration. Similarly, Ly-6Clow, Ly-6Cintermediate cells main-
tained their ability to suppress proliferation (Figure 5C)
even when co-cultures were stimulated with LPS. In
contrast, Ly-6Chigh actually significantly increased the
proliferation of responder immune cells (Figure 5C) fol-
lowing stimulation with LPS. These results demonstrate
that RA Ly-6Clow and Ly-6Cintermediate cells are the sup-
pressive population and are able to maintain suppressive
abilities even in the presence of inflammatory (LPS)
challenge. Phenotypically, RA Ly-6Clow cells showed the
most marked increase in the percentage of PD-L1+, as
well as, CD86+ and MHC class II+ cells, with over 90%
of the Ly-6Clow cells expressing PD-L1 (Figure 6). A
similar but less dramatic phenotype was seen in the Ly-
6Cintermediate cells (data not shown). Taken together,these data show that RA induces a small but potent
population of CD11b+ CD11c- Ly-6Clow/intermediate
MCregs consistent with an activated regulatory mono-
cyte phenotype that are able to suppress immune cell
proliferation.
Discussion
The principal objective of this study was to determine
whether RA, a steroid hormone known to play import-
ant roles in regulating both mucosal immune responses
and differentiation of myeloid cells could generate an ac-
tivated (or mature) MCreg population. We demonstrate
that RA influences myelopoiesis to a regulatory MCreg
(monocyte) with the phenotype of CD11b+ CD11c-Ly-
6Clow/intermediate but fails to induce DCregs. These cells
can influence both CD4+ and CD8+ responses and pro-
mote FoxP3+ (Treg) cell induction. Our data suggest that
RA has distinctly different effects on monopoiesis and
dendropoiesis to promote the generation of regulatory
monocytes.
MCregs are a diverse population of cells and much at-
tention has focused on the in vitro generation and clin-
ical application of MCregs. While the in vitro generation
of such MCreg populations has great therapeutic
Figure 4 RA generated CD11b+ BM-MCs suppress T cell proliferation and express a regulatory phenotype. CD11b+ CD11c- were purified
from BM-MCs by sequential purification of CD11b+ cells from the CD11c- fraction and purity determined to be >95%. Cells were routinely stained
for cell surface markers and flow cytometry performed using the BD Accuri C6 Flow cytometer. CD11b+ CD11c cells were (A) assessed for expression of
maturation markers CD80, CD86, MHCII, PD-L1 and PD-L2 (B) co-cultured with responder immune cells for 96 hours with media or anti-CD3 stimulation
and then pulsed with H3 thymidine in the final 18 hours of culture, (C) intracellular cytokine staining (IL-17, INF-γ, IL-4) of CD4+ cells performed
and (D) co-cultured with activated CTLs and a T lymphoma cell line with cell viability assessed by the MTT assay. Data is representative of three
separate experiments. * = p < 0.05 (A-C) Data shown is a representation of 3 experiments (D).
VanGundy et al. BMC Immunology 2014, 15:8 Page 7 of 14
http://www.biomedcentral.com/1471-2172/15/8potential, much remains to be learned regarding the fac-
tors which contribute to MCreg induction. The majority
of in vitro generated MCregs are arrested in an immatureor hypo-functional state. An emerging concern is that
these immature MCregs populations may mature to become
inflammatory DCs or macrophages and, thus, contribute to
Figure 5 RA CD11b+ CD11c-Ly6Clow/intermediate are the suppressive population. BM cells were differentiated in the presence of GM-CSF with
or without 100 nM RA for 7 days, stained with fluorescently-labeled antibodies against CD11c, CD11b+, and Ly-6C to determine relative expression
of Ly6C on CD11b+ CD11c cells (A). Cells were then sorted based on relative Ly6C expression and purified populations co-cultured with antigen-specific T
cell receptor transgenic T cells for 96 hours with media, peptide or LPS and fold change in proliferation shown for peptide-stimulated (B) or LPS-stimulated
(C) co-cultures. Data are representative of at least three separate experiments. * = p < 0.05.
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recent approach is to induce mature MCregs which would
be stable and maintain regulatory potential in an inflamma-
tory environment [22,32,65,66]. Anderson and colleagues
have demonstrated that human DCregs (generated with
dexamethasone, vitamin D and LPS) maintain tolerogenic
activity and actually induce significantly higher levels of
IL-10 production by resultant T cells [33]. However, the
relative stability and ability of MCregs (such as DCregs) to
maintain regulatory abilities during inflammation may
still be in question. For example, a study by Voigtlander
et al. suggests that DCregs induced by TNF-alpha do not
maintain their regulatory abilities upon a secondary
stimulation with TNF-alpha in vivo [34]. Obviously, this
is of considerable concern given that TNF-alpha is
present in a large array of inflammatory conditions
where such DCregs (or other MCreg populations) may be
applied therapeutically. Much work remains to deter-
mine critical factors important in generating mature
MCregs for anti-inflammatory therapies but we have fo-
cused on non-inflammatory pathways to induce mature
MCregs.
We have shown that mature MCregs can be generated
with the use of steroid hormones alone [35]. Our previous
work has shown that the sex steroid hormone estriol (E3)
induces a mature activated MCreg population of CD11c
+DCregs that protects against inflammatory challenge
in vitro and in an in vivo disease model [35]. In the
present study, we have extended our research of pathways
involved in normal homeostatic induction of mature
MCregs by investigating the ability of the steroid hormone
RA to induce mature MCregs that are resistant to inflam-
matory challenge. Our results show that RA is more ef-
fective than E3 in vitro in generating MCregs and that
these MCregs are resistant to LPS inflammatory challenge.
RA is known for its ability to promote the differenti-
ation, and maturation, of myeloid cell populations. This
ability, along with its known immunoregulatory role at
mucosal sites, made it a logical candidate for these stu-
dies [44,52]. RA is present in relatively large concen-
trations within mucosal sites and is largely produced by
local antigen presenting cells (APCs) residing within these
mucosal sites. Specifically, mucosal CD103+ DCs are the
primary immunoregulatory myeloid cells within the gut.
These DCs have up-regulated raldh2 gene expression, con-
stitutively produce RA, and produce increased TGF-beta.
They also have a significant ability to induce Foxp3+ Tregs,
mucosal homing receptors CCR9 and α4β7 expression on
lymphocytes and enhance antibody production and Ig iso-
type switching [6,9,36,57]. These mucosal DCs are the most
common MCs investigated regarding RA biology and in-
duced mucosal DCs have been generated from monocytes
Figure 6 CD11b+ CD11c- Ly-6Clow cells have an activated regulatory phenotype. BM-MCs were differentiated with or without 100 nM RA
for 7 days. Myeloid populations were separated by Flow sorting on the FACS Aria III by antibodies CD11c and Ly-6Clow/int and extracellular
markers (CD80, CD86, MHCII, and PD-L1) were assessed on the Accuri C6 flow cytometer. Data are representative of three separate experiments.
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row precursors with RA [18,41,57,67,68]. Increasingly, the
non-mucosal and therapeutic applications of RA (i.e. in
cancer) are being investigated [9,19,43,44,53] and this study
focused on RA’s ability to induce mature activated MCregs
that are able to suppress responder immune cell prolifera-
tion [8,35,41,43,57,69].
Given RA’s critical role in DC-mediated immunore-
gulation within the gut, it was quite surprising that RA
CD11c+ cells were not suppressive. One possibility is that
DC’s differentiated with RA could generate mucosal DCs
but wouldn’t generate mature activated DCregs that could
suppress proliferation as seen with E3 DCregs. While induc-
tion of mucosal DCs can be accomplished with RA [18,43],
the immunomodulatory abilities of these DCs as described
in these studies was not the focus of this study. Alterna-
tively, timing of RA administration may have resulted in
the lack of DCreg induction as described by Feng and col-
leagues [41]. Specifically, their studies showed that the pres-
ence of 1 μM RA from day 0 throughout differentiation
failed to induce mucosal DCs. Although different dosages
and criteria were used to generate and identify DCs as mu-
cosal (versus DCregs in our study), the continuous presence
of RA during differentiation may have resulted in the in-
ability to induce DCregs in our study. Similarly, Wada’s
group showed that the use of a synthetic RARα and β agon-
ist (AM-80) could differentiate human peripheral blood
monocytes into dendritic cells that have a tolerogenicphenotype and function [18]. The use of AM-80 versus
ATRA in our study or the differentiation of human mono-
cytes versus murine myeloid progenitors could explain the
differences in DCregs versus MCregs in our study.
It could be argued that CD11c- DC precursors existed
within the population of CD11b+ CD11c- suppressive
cells. Given the described effects of RA in promoting
differentiation and maturation, in conjunction with our
data demonstrating an activated phenotype, we believe
this to be unlikely [57,70-72]. Rather, our data on Ly6C
expression strongly support that the suppressive cells
were regulatory monocytes with an activated regulatory
phenotype (increased CD80, CD86, MHC class II and
PD-L1) consistent with previous work within our lab.
Given that the CD11b+ CD11c- population is comprised
less than 20% of the entire population, the ability of
these cells to suppress both CD4+ and CD8+ responses
is noteworthy. The specific contributions of cell contact-
dependent (i.e. PD-L1) versus cell contact-independent
(i.e. IL-10, TGF-beta, etc.) mechanisms responsible for
the regulatory abilities of these cells was beyond the
scope of this study. However, we did see increases in
regulatory markers including PD-L1, IL-10 and the per-
centage of FoxP3+ cells with RA MCregs.
Monocytes are circulating myeloid cells which give rise
to tissue DCs and macrophages, and their regulatory abil-
ities have recently been recognized [7]. Although numer-
ous markers can be present on mouse monocytes (e.g.
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investigate Ly6C expression levels given that they have
been correlated with monocyte function [7,63,71,73]. Spe-
cifically, Ly-6Chigh represents an inflammatory monocytes
while, Ly-6Clow/intermediate monocytes have been shown to
play important roles in patrolling the vasculature and po-
tentially resolving inflammation and tissue repair
[7,63,74-76]. Ly6C is also down regulated following differ-
entiation which is consistent with our findings where RA,
a molecule known to promote differentiation and matur-
ation, increases the percentage of cells that are Ly-6Clow/
intermediate (Figure 5A) [3,44]. Our data suggest that Ly-6C
levels correlate with suppressive abilities with the lowest
Ly-6C expression associated with the most suppressive
ability. Given that Ly-6Chigh monocytes are typically in-
flammatory monocytes, it is not surprising that prolifera-
tion is actually enhanced following LPS stimulation in this
cell population (Figure 5C). Taken together, these data
showed a progression from Ly-6Chigh to Ly-6Clow associ-
ated with increasing regulatory abilities. These results are
consistent with the association seen between Ly-6C ex-
pression and blood monocyte function described by others
[7,63,71,77]. Currently, the mechanisms and pathways by
which RA maturation of monocytes imparts them with in-
creased regulatory abilities remain undefined. Whether a
specific signal during differentiation drives monocytes to
become regulatory in an active process or whether differ-
entiation under homeostatic or regulatory (i.e. RA) condi-
tions in the absence of inflammatory stimuli is a default
mechanism for regulatory monocyte induction is un-
known. Additionally, whether these RA Ly-6Clow/intermedi-
ate monocytes have the potential to further differentiate
into DCreg or regulatory macrophage populations remains
to be determined and is the subject of ongoing studies
within the laboratory [7].
Conclusion
Our findings show that continuous RA exposure during
myelopoiesis promotes the induction of MCregs. Specific-
ally, RA induced CD11b+ CD11c-Ly-6Clow/intermediate regu-
latory monocytes which suppressed the proliferation of
immune cells but RA failed to induce DCregs. Our data
suggests that RA has unique effects on different myeloid
populations during differentiation that may influence the
regulatory abilities of monocytes and DCs. A more thor-
ough understanding of how RA mediates these differential
effects has important implications in our understanding of
MCreg biology and the potential application of these cells
to treat a wide variety of inflammatory diseases.
Methods
Mice
C57BL/6 (H-2b) mice (4–8 wk old), C57BL/6-Tg (TcraTcrb)
425Cbn/J, C57BL/6-Tg(Tcra2D2,Tcrb2D2)1Kuch/J andreporter Foxp3EGFP (B6.Cg-Foxp3tm2Tch)) were purchased
from Jackson Laboratories (Bar Harbor, ME, USA) or bred
in-house. Mice were housed five per cage and maintained
on a 12 hr. light/dark cycle, maintained under specific
pathogen-free conditions and were housed and cared for
according to the institutional guidelines of the Ohio State
University’s Institute for Animal Care and Use Committee.
Cell lines
EG7 and EL7 (kindly provided by P. Boyaka, Ohio State
University) were used to study the MHC class I-re-
stricted response of CTLs in mice. The EG7 cells have
been transfected with plasma to synthesize and constitu-
tively secrete OVA 257–264 peptide and should be cul-
tured in 10% RPMI. The EL4 cells are the non-OVA
secreting duplicate of the EG7. Both are commonly
found at ATCC but were acquired through Dr. Boyaka.
The DC2.4 cell line was kindly provided by K. Rock,
University of Massachessetts and as a DC antigen-
presenting cell.
BM-MC differentiation and development of regulatory MC
differentiation model
Bone marrow (BM) cells were collected from C57Bl/6
mice femurs and tibias. After erythrocyte lysis (AKC or in-
house lysis buffer), cells were cultured with RPMI 1640
(Invitrogen) supplemented with 10% FBS, 25 mM HEPES,
2 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml strepto-
mycin, 5 × 10-5 M 2-mercaptoethanol and 200U/ml re-
combinant murine GM-CSF (R&D Systems) ± 100 nM of
either estriol (E3) or all-trans retinoic acid (RA) (Sigma-
Aldrich) for 6–7 days at a density of 2 × 106 cells/ml. Day
6–7 cells were considered differentiated BM-MCs (media
control) and BM-MCregs(RA and E3). Cells were chal-
lenged with inflammatory stimulus LPS (1 μg/ml, 055:B5,
Sigma-Aldrich) during culture as indicated at day 6 or
later for BM-DCs.
Functional immunosuppressive assays: T cell
proliferation assay
Myeloid cells (BM-MCs or BM-MCregs) were cultured
with responder spleen cells from antigen-specific T cell
receptor transgenic (TCR Tg; where antigen was either
OVA323-339 or MOG35-55) or Foxp3EGFP mice as in-
dicated. To assess T cell proliferation co-cultures were
stimulated with anti-CD3 (BD Bioscience), T cell-receptor
specific antigen MOG35-55 (Bio Matic) or T cell-receptor
specific antigen OVA 323–339 (Anaspec). To assess the
effects of myeloid cell activation, co-cultures were stimu-
lated with LPS from Escherichia coli, 055:B5 (Sigma-Al-
drich) for 96 hours, pulsed with (H3 thymidine) (Perkin
Elmer Life Sciences or MP Biomedicals) in the last 18
hours, harvested and counted, data is expressed as counts
per million (cpm) ± SEM [35].
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To generate CTL, spleen and lymph nodes (LN) were
removed from OT-1 mice and co-cultured with OVA
(257–264) pulsed DC2.4 cells (kindly provided by
Kenneth Rock, University of Massachussets) for 4 days,
removed and cultured with mrIL-2 (R&D Systems) for 2
days. OVA-expressing (EG7) and non-transfected con-
trol cells (EL4) were seeded at 2 × 104 cells per well and
co-cultured with CTLs (1 × 105) and control or RA
treated monocytes (2 × 104) for 6–18 hours [73,78]. The
MTT assay (Sigma-Aldrich) was used to determine
quantity of live cells. Briefly, after incubation, cells were
centrifuged (1500 RPM for 5 min) media was decanted
and 100 ul of fresh media was added. 10ul of 5 mg/ml
thiazolyl blue tetrazolium bromide (MTT) was added to
each well for 2 hours at 37°C. After incubation cells were
centrifuged (1500 RPM for 7 min) and media was dec-
anted, cells were allowed to dry for 15–30 min before
100 ul of DMSO was added, mixed well and read at
570 nm on a Spectra Max 2. The absorbance levels were
calculated by averaging the non-specific and specific ab-
sorbance levels of five separate data sets. Media control
is compared to RA treated cells.
In vitro Treg induction
Bone marrow (BM) cells were collected from C57Bl/6
mice femurs and tibias. After erythrocyte lysis, BM cells
were cultured with supplemented RPMI (as previously
described) for 7 days at a density of 2x106 cells/ml +/−
RA. Spleens from mice with reporter Foxp3EGFP (B6.
Cg-Foxp3tm2Tch)) were harvested, passed through cell
strainers (70 μm, BD Falcon), collected by centrifugation
(1500 RPM for 7 Min at 4°C) and subjected to erythro-
cyte lysis. Responder cells and MCs or CD11c- MCs
were cultured for 4–6 days and aliquots from cultures
assessed for Foxp3 expression by flow cytometry.
Flow cytometry
In vivo and in vitro derived DCs and MCs were labeled
and evaluated by three-color flow cytometry using com-
bination of the following conjugated directly antibodies
(clone): CD11c (HL3), CD11b (M1/70), Gr-1 (RB6-8C5),
Ly-6G (1A8), Ly-6C (AL-21), MHC class II (AF6-120.1),
CD80 (16-10A1), CD86 (IT 2.2), PD-L1 (MIH5), and
PD-L2 (YT25) with appropriate isotype controls. (BD
Bioscience, eBiosciences or Miltenyi Biotec). Cells were
stained with fluorochrome-labeled antibodies or isotype
controls for 20 min in the dark at 4°C, washed twice in
FACS buffer and re-suspended in 300 μl FACS buffer for
flow cytometry analysis.
Intracellular IL-10, IL-4, IL-17 and INF-γ levels were
measured after incubating myeloid cells with 1 μg/ml
LPS overnight (IL-10) or Ionomyocin (1 mg/ml) and
PMA (25 ng/ml) for 4 hours (IL-4, IL-17, and INF-γ).2 μM of Monensin (eBioscience) added 2–4 hrs. before
harvesting cells. Cells were removed from culture,
washed with 2 ml of supplemented RPMI and blocked
with 0.5 μg/ml Fc block (anti-CD16/CD32) for 15 mi-
nutes. Cells that required extracellular markers were
re-suspended in FACS buffer and stained with anti-
CD4 (0.2 mg/ml) and incubated in the dark at 4°C for
20 min. Cells were washed with FACS buffer (2x with
1 ml) and then fixed and permeabilized using FIX/
PERM solution (BD Bioscience), briefly vortexed and
incubated in the dark at 4°C for 20 min. Cells were
then washed twice with 1 ml of PERM/WASH buffer
(BD Bioscience), re-suspended in PERM/WASH buf-
fer and stained with 0.2 mg/ml anti-IL-10 (BD Bio-
science) for 30 min. in the dark at 4°C. All flow samples
were processed on an Accuri C6 flow cytometer and re-
sults analyzed using the Accuri C6 Flow software (BD
Biosciences).
Myeloid cell purification
Day 6–7 differentiated BM cells were incubated with manu-
facturer suggested amounts of CD11c/CD11b microbeads
(Miltenyi Biotec) for 15 minutes in the dark at 4°C. Cells
were washed with running buffer (10% FBS in PBS with
900 mg of NaN2 per 1 L of PBS), and centrifuged (1500
RPM, 7Min). Cell separation was performed using either
the Auto Macs (Miltenyi Biotec) magnetic separation
instrument or the FACS Aria III 12 color, 4 laser cell
sorter. The Auto Macs was used according to the man-
ufacturer’s instructions. Cell sorting with the FACS
Aria III was performed at the OSU Flow Cytometry
Core and isotype control antibodies were included to
determine detection levels. CD11b+ CD11c- Ly-6Clow
monocyte populations were serially gated on CD11c-
cells, followed by CD11b+ with gates set around dis-
tinct populations of Ly-6C low, intermediate and high.
The purity of the cell populations was ≥95%.
Statistical analysis
Data are represented as mean +/− SEM or fold change.
Statistical significance was determined using a Student’s
t-test or 1 way ANOVA with a significance level (p-
value) < 0.05 and the Wilcoxen signed-rank test. All ana-
lyses were performed using Excel and/or GraphPad
Prism software (La Jolla, CA).
Additional files
Additional file 1: Figure S1. GM-CSF induced myeloid cells. BM-MCs
were differentiated for 6–7 days and characterized phenotypically using
the Accuri C6 Flow cytometer to identify the relative percentage of the
cell population expressing (A) of CD11c+ and CD11b+ media and RA
differentiated cells. Expression of LY-6G was evaluated by the Accuri C6
cytometer of the (B) CD11b+ cells. Data are representative of at least
three separate experiments.
VanGundy et al. BMC Immunology 2014, 15:8 Page 12 of 14
http://www.biomedcentral.com/1471-2172/15/8Additional file 2: Figure S2. CD11c- IL-10 and Treg cell induction. Bone
marrow cells were differentiated in the presence of GM-CSF with
or without 100 nM of or retinoic acid over 7 days to generate BM-MCs.
Following differentiation MCs were magnetically labeled with CD11c+ beads
and separated with the AutoMacs. Purity was confirmed by routine staining
of positive and negative cells with FITC-conjugated anti-CD11c antibody
and cells were run on the Accuri C6 Flow cytometer. (A) The relative
percentage of IL-10+ cells was determined in control MCs and RA MCregs.
Data are representative of at least three separate experiments. (B) Day 7
media CD11b+ CD11c- MCs or RA CD11b+ CD11c-MCs were co-cultured in
the presence of Foxp3EGFP reporter cells and expression of Foxp3+ cells
was evaluated in the lymphocyte population over time in the cultures by
flow cytometry. Data shown is a representation of 3 experiments.
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